Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase II...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Lin, Li, Snider, Jacqueline, Prat, Aleix, Parker, Joel S., Luo, Jingqin, DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura J., Unzeitig, Gary W., Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, Joseph M., Watson, Mark A., Leitch, Marilyn, Hunt, Kelly, Olson, John A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107749/
https://ncbi.nlm.nih.gov/pubmed/21555689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6950
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados